In Thailand, platelet product from a blood donor was transfused to a recipient who had dengue. Two days later, the donor was confirmed to have monkeypox virus infection. Monkeypox virus DNA was undetectable in recipient specimens up to 2 weeks after transfusion. The recipient remained asymptomatic at 4 weeks of monitoring.

DOI: http://doi.org/10.3201/eid3003.231539

Monkeypox virus (MPXV), a double-stranded DNA virus that primarily infects rodents in sub-Saharan Africa, causes mpox disease. MPXV is a member of the genus Orthopoxvirus in the family Poxviridae. MPXV clade I is endemic to Central Africa and clade II to West Africa. Clade II is further subdivided into IIa and IIb. Strains from the recent global emergence appear to belong to clade IIb (https://nextstrain.org/mpox/all-clades).

The potential to unknowingly transmit MPXV from donated blood products exists despite routine stringent screening of bloodborne pathogens at donation centers. Thailand first reported mpox in a 27-year-old male tourist from Africa in Phuket province on July 21, 2022; nonoutbreak sporadic infections have since been identified (1). By May 2023, ≈40 infections had been laboratory-confirmed. Infections surged after Pride Festivals, which took place in Bangkok and Pattaya City in June 2023; infections peaked in August and then declined. As of November 4, 2023, the Ministry of Public Health Thailand (MoPH) had identified 582 infections (563 male and 19 female patients; median age 33 years, age range 1–64 years) and 2 deaths. Here, we describe an unintended administration of platelets from an MPXV-infected donor to a dengue-infected recipient and the subsequent follow-up to monitor for potential MPXV transmission.

On July 24, 2023, an apparently healthy 22-year-old man donated whole blood at the National Blood Center (NBC) of the Thai Red Cross in Bangkok (Figure). That afternoon, he experienced fever and malaise. On July 26, itchy skin rash and lesions appeared on his hands, feet, and anus, which prompted him to go to a hospital. His doctor sought consultation with the Department of Disease Control at MoPH, where samples of the skin lesion, oropharyngeal swab, and plasma were tested for MPXV by real-time PCR to detect the F3L gene region (BioPerfectus, https://www.bioperfectus.com). MPXV DNA was detected only in the lesion (cycle threshold [Ct] 21.7) and oropharyngeal (Ct 31.5) swab samples.

NBC processes blood donations individually and routinely screened for hepatitis B/C and syphilis. Derived products from donations are primarily leukocyte-poor red cells, leukocyte-depleted pooled plate-
let concentrate, and fresh frozen plasma, prepared in accordance with guidelines of the European Directorate for the Quality of Medicines & Healthcare (2). Specifically, the platelet concentrate is prepared from a pool of 4 donor buffy coats of the same ABO blood group, diluted with either plasma from one of the buffy coat donations or a platelet additive solution, centrifuged to separate the platelets, filtered to deplete leukocyte, and stored for bacterial testing before distribution.

On July 31, the NBC was alerted to the potential of an MPXV-contaminated donation, which prompted recalls of all blood components derived from the 22-year-old donor. That same day, red blood cells and plasma derived from the donor materials were successfully retrieved and destroyed; however, the platelet concentrate had already been administered to an 11-year-old female recipient who had ongoing dengue infection.

To characterize MPXV in the donation, our laboratory received residual donor plasma and red cells that the NBC had, from which we extracted DNA by using the magLEAD 12 gC instrument (Precision System Science, https://www.pss.co.jp) according to the manufacturer’s instructions. We tested for MPXV DNA by generic real-time PCR to detect the tumor necrosis factor receptor gene located at the terminal inverted repeat region on the MPXV genome, in accordance with the US Centers for Disease Control and Prevention protocol (3). We confirmed the result using conventional PCR to amplify the DNA helicase and Schlafen protein genes (Appendix, https://wwwnc.cdc.gov/EID/article/30/3/23-1539-App1.pdf). We Sanger sequenced amplicons, and deposited nucleotides into GenBank (accession nos. OR790439–40).

Plasma yielded detectable MPXV DNA (Ct ≈35); red blood cells did not. Phylogenetic analysis of the DNA helicase gene sequence suggests that the MPXV strain in the donor belonged to clade IIb (lineage B) and genetically clustered with strains previously identified in Taiwan, Japan, and the United States (88% bootstrap support) (Appendix Figure).

MPXV DNA was undetectable in serum and throat swab samples collected from the platelet recipient on August 1, 3, 7, and 14. No mpox-associated symptoms were evident 4 weeks posttransfusion. Incubation period for mpox is 3–17 days (mean 8.5 days) (4,5).

We posit that there was a low risk for transfusion-transmitted infection for several reasons. First, detection of MPXV DNA in the residual donated plasma does not indicate infectious virus, as was shown...
in a viral load study using cell culture as surrogate for infectivity (6). Thus, nucleic acid detection does not prove the presence of viable or infectious virus, as Cohen et al. demonstrated in a smallpox-vaccine study (7). We pooled and extensively prepared platelet products from multiple donors, which may have diluted out any residual virus before transfusion 1 week later. In conclusion, our study shows that a blood donation from a donor with detectable MPXV viral DNA did not appear to transmit the infection to a pooled-platelet recipient.

This work was supported by the Health Systems Research Institute, the National Research Council of Thailand, the Center of Excellence in Clinical Virology, Chulalongkorn University, King Chulalongkorn Memorial Hospital, the MK Restaurant Group and Aunt Thongkam Foundation, and the BJC Big C Foundation. J.P. reports financial support from the Second Century Fund Fellowship of Chulalongkorn University.

About the Author
Dr. Puenpa is a postdoctoral fellow at the Center of Excellence in Clinical Virology in the Faculty of Medicine at Chulalongkorn University. Her primary research interests are molecular epidemiology and evolution of human enteroviruses.

Reference

DOI: https://doi.org/10.3201/eid3003.231638

The invasive Anopheles stephensi mosquito has rapidly expanded in range in Africa over the past decade. Consistent with World Health Organization guidelines, routine entomologic surveillance of malaria vectors in Accra, Ghana, now includes morphologic and molecular surveillance of An. stephensi mosquitoes. We report detection of An. stephensi mosquitoes in Ghana.

Anopheles stephensi is an invasive mosquito species originating from parts of Southeast Asia and the Arabian Peninsula (1). Over the past decade, An. stephensi mosquitoes have been expanding in range and have now been documented in several countries in Africa (2). First detected in Djibouti, on the Horn of Africa, in 2012, this vector has been implicated in urban malaria outbreaks (3). They were also detected in Ethiopia in 2016 and 2018 (4,5). An. stephensi mosquitoes were subsequently detected in Sudan (2016), Somalia (2019), Nigeria (2020), and Kenya (2023) (2,3,5–7). This invasive vector poses a major threat to current malaria control and elimination efforts. The ability of An. stephensi mosquitoes to breed in artificial containers enables them to thrive in urban areas, setting them apart from other major